Hwaseong Jeon's Startup Morning Coffee #1093: Technological Innovation

The YouTube program 'Startup Morning Coffee,' hosted by CEO Jeon Hwa-sung, goes live to viewers daily at 8:40 AM on the 'Jeon Hwa-sung's CNTV' channel. It deeply introduces the core competencies and market potential of promising startups, positioning itself as a valuable information platform for those interested in the startup ecosystem. Interactive communication through real-time comments adds vitality to the program. The company that recently garnered attention on this program is 'Phycell'. Phycell aims to be a total solution provider in the field of advanced regenerative medicine, particularly leading innovation in natural killer cell (NK Cell) culture technology, which plays a crucial role in cancer prevention and treatment. Their core competitiveness lies in 'PNK1,' a substance they developed in-house and patented. 'PNK1' is a unique technology that dramatically increases the proliferation efficiency of NK cells by more than 10 times compared to conventional culture media. It enables the culture of high-purity NK cells and stem cells, demonstrating the potential to open new horizons in the advanced regenerative medicine market. Currently, Phycell is participating in CNT Tech's Kibo Venture Camp program, accelerating the commercialization of its technology. Phycell's core vision is to build a diversified business model based on this high-efficiency NK cell culture technology. They are targeting entry into Korea's 50 billion won regenerative medicine market, pursuing advanced regenerative medicine service consulting, sales of high-quality cell culture media, and cell CDM (Contract Development and Manufacturing) businesses. In particular, they plan to establish their own production facilities to secure a robust revenue structure through stable cell supply and media sales. Through this, they have set a concrete goal to achieve 1.4 billion won in sales by 2027, surpass the break-even point, and achieve continuous growth. CEO Jeon Hwa-sung expressed strong anticipation for Phycell's innovative technology and future growth potential through a 'one-point comment.' He emphasized, "Phycell's NK cell and stem cell culture technology will play a crucial role in the advanced regenerative medicine market, and particularly, the potential of the patented substance 'PNK1' which maximizes NK cell culture efficiency, along with the capabilities of the experienced founding team, will drive Phycell's exponential growth in the future." He thus presented a positive outlook for the future Phycell is poised to create. Equipped with both technological prowess and business viability, Phycell is preparing to emerge as a key player in the future regenerative medicine market.